標題: Titlebook: Bispecific Antibodies; Roland E. Kontermann Book 2011 Springer-Verlag Berlin Heidelberg 2011 Cancer therapy.Hybridoma.Immunoglobulin.Immun [打印本頁] 作者: invigorating 時間: 2025-3-21 20:08
書目名稱Bispecific Antibodies影響因子(影響力)
作者: 小爭吵 時間: 2025-3-21 22:45 作者: 開頭 時間: 2025-3-22 01:55
,Allgemeine physikalische Hilfss?tze,ill present an overview of work that have been published, including a brief introduction to the particular molecular scaffolds with the structural basis and some of the biophysical and biochemical properties before describing the bispecific application.作者: Affirm 時間: 2025-3-22 07:44
Die Technik der kystoskopischen Untersuchunghe biochemical and biophysical properties and the manufacturability of BsAb. This chapter reviews the current advances in design and engineering of the IgG-like BsAb in the context of their potential clinical applications.作者: TAIN 時間: 2025-3-22 10:36 作者: Explicate 時間: 2025-3-22 14:10
Alternative Scaffolds as Bispecific Antibody Mimetics,ill present an overview of work that have been published, including a brief introduction to the particular molecular scaffolds with the structural basis and some of the biophysical and biochemical properties before describing the bispecific application.作者: Inclement 時間: 2025-3-22 20:43
The Design and Engineering of IgG-Like Bispecific Antibodies,he biochemical and biophysical properties and the manufacturability of BsAb. This chapter reviews the current advances in design and engineering of the IgG-like BsAb in the context of their potential clinical applications.作者: llibretto 時間: 2025-3-22 21:18
The Dock-and-Lock (DNL) Approach to Novel Bispecific Antibodies, AD module occurs spontaneously, and the resulting complex is locked with disulfide bonds to enhance in vivo stability. This new platform technology provides a versatile approach to create novel bispecific antibodies of multiple valencies, with potential applications in the detection and therapy of diverse diseases.作者: 莎草 時間: 2025-3-23 02:31 作者: Hormones 時間: 2025-3-23 07:28
ose new to the field.With contributions by international exp.The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the 作者: 嫌惡 時間: 2025-3-23 10:28
Zentralprojektion (Perspektive)d V. domain, Fv molecules suffer from instability, which can be improved by connecting the two domains with a flexible peptide linker. These single-chain Fv (scFv) fragments can be easily produced in prokaryotic and eukaryotic systems and represent the prototype recombinant antibody format.作者: Entropion 時間: 2025-3-23 16:06
Pathologie der Harnleitermündungr cancer immunotherapy, interferon α for melanoma therapy (FDA approved in 1995) and others, such as IL-15 emerged as good candidate since IL-15 was ranked 1st/124 immunomodulatory drugs in clinical and preclinical trials to treat cancer by an NCI consortium (Cheever 2008).作者: 音樂等 時間: 2025-3-23 20:14 作者: magnanimity 時間: 2025-3-24 02:13
Bispecific Antibodies for the Retargeting of Cytokines,r cancer immunotherapy, interferon α for melanoma therapy (FDA approved in 1995) and others, such as IL-15 emerged as good candidate since IL-15 was ranked 1st/124 immunomodulatory drugs in clinical and preclinical trials to treat cancer by an NCI consortium (Cheever 2008).作者: 平 時間: 2025-3-24 06:04
Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy,f BiAbs and their combinations for targeting effector cells to tumor cells. This chapter focuses on the use of BiAbs to redirect non-MHC-restricted . expanded T cells as a therapeutic platform directed at various tumor-associated antigens ..作者: Feckless 時間: 2025-3-24 06:56
Bispecific Antibodies for Diagnostic Applications,nfectious diseases. This chapter describes the use of BsMAb for the detection of ., . O157:H7, ., ., .. Further, BsMAb have been utilized for diagnosis of various types of cancers. The use of BsMAb in detection of prostate cancer and in cancer diagnostic imaging is also discussed.作者: 調(diào)味品 時間: 2025-3-24 13:38
https://doi.org/10.1007/978-3-7091-8778-45). This early experiment showing expression of both parental immunoglobulin genes in the hybrid cell was performed to better understand allelic exclusion, whereby under normal conditions each B lymphocyte produces antibodies encoded by only one of two possible alleles.作者: Occupation 時間: 2025-3-24 15:40
Zentralprojektion (Perspektive) recruiting natural killer (NK) cells and macrophages as cytotoxic effectors via the trigger CD16. The sctb 123-16-33 is a prototypical example of “dual-targeting” agent specific for CD123 and CD33 on acute myeloid leukemia cells. The anticipated benefits of dual- over mono-specific targeting and of the triplebody format in general are outlined.作者: 血統(tǒng) 時間: 2025-3-24 19:50 作者: REIGN 時間: 2025-3-24 23:45 作者: Injunction 時間: 2025-3-25 05:47
Book 2011studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications wer作者: fidelity 時間: 2025-3-25 10:03 作者: CRAFT 時間: 2025-3-25 12:31 作者: Intend 時間: 2025-3-25 18:37 作者: ROOF 時間: 2025-3-25 23:21 作者: sperse 時間: 2025-3-26 03:23 作者: Anticlimax 時間: 2025-3-26 04:25 作者: BALE 時間: 2025-3-26 08:59 作者: 感激小女 時間: 2025-3-26 15:45 作者: 艦旗 時間: 2025-3-26 17:32 作者: ELATE 時間: 2025-3-27 00:02 作者: BINGE 時間: 2025-3-27 02:50
Die Technik der kystoskopischen Untersuchungble two different monospecific binding units into one molecule, two-in-one antibodies are dual-specific antibodies that can be produced as conventional IgG, in which each of the two identical Fab arms recognizes two distinct antigen epitopes. The first proof-of-concept two-in-one bH1 has been select作者: OMIT 時間: 2025-3-27 08:53
Pathologie der Harnleitermündung existing repertoires of such agents as produced by genetic engineering alone, we envisioned and developed the Dock-and-Lock (DNL) method, which enables site-specific conjugation of two modular components only with each other, producing a covalent construct of defined composition with retained bioac作者: 連鎖 時間: 2025-3-27 13:24
Pathologie der Harnleitermündungherapy. For redirecting cytotoxic effector cells against tumors, typically the first binding site of a bispecific antibody recognizes a tumor-associated antigen, whereas the second site engages a stimulatory trigger molecule on effector cells. The adequate choice of the trigger molecule offers the o作者: 變白 時間: 2025-3-27 14:55
Technik des Harnleiterkatheterismusrty enables the development of therapeutic strategies that are not possible with conventional monoclonal antibodies (mAbs). Advances in antibody engineering and the expanding knowledge of antigen profiling on malignant cells have provided innovative solutions for the development of various formats o作者: circumvent 時間: 2025-3-27 20:30 作者: DNR215 時間: 2025-3-28 00:04 作者: 激怒某人 時間: 2025-3-28 03:19 作者: NEXUS 時間: 2025-3-28 09:13
Technik des Harnleiterkatheterismuss are being pursued, including long-term gene correction of monogenetic diseases, eradication of tumor cells in cancer patients, or genetic vaccination for infectious diseases. Bispecific antibodies and gene therapy are connected in two ways. First, bispecific antibodies are tools of interest for th作者: 睨視 時間: 2025-3-28 12:24
Die Technik der kystoskopischen Untersuchungity to simultaneously bind to a specific antigen and a given detection moiety enables them to function as excellent bifunctional immunoprobes in diagnostic assays. BsMAb are being exploited for the development of simple, rapid, and highly sensitive immunoassays for diagnosis of bacterial and viral i作者: Antimicrobial 時間: 2025-3-28 15:07
Die Technik der kystoskopischen Untersuchunglls (Perez et al. 1985; Staerz et al. "CR60">1985). In vitro, this approach was extremely potent, highlighting the superiority of T-cell-induced compared to accessory cell-mediated killing. But two major drawbacks hampered the rapid transition of this new approach from preclinical investigations to successful clinical trials and market approval.作者: AMOR 時間: 2025-3-28 21:00
Roland E. KontermannPresents the recent advances in antibody engineering and in the various clinical applications.An invaluable resource for both experts and those new to the field.With contributions by international exp作者: 口訣 時間: 2025-3-29 02:37 作者: Nausea 時間: 2025-3-29 05:52 作者: 手段 時間: 2025-3-29 11:15
978-3-642-43207-1Springer-Verlag Berlin Heidelberg 2011作者: 秘傳 時間: 2025-3-29 12:14 作者: Blemish 時間: 2025-3-29 17:32
,Ern?hrung und Ern?hrungsst?rungen, can be further improved by protein and/or glyco-engineering (Carter 2006; Kubota et al. 2009). However, natural antibodies also face certain limitations. For example, antibodies are not capable of recruiting T cells because these cells do not express Fc receptors. Also, monoclonal antibodies are mo作者: bisphosphonate 時間: 2025-3-29 21:34 作者: blithe 時間: 2025-3-30 01:46
Die Symmetrieeigenschaften der Kristalle,em as ideal building blocks to elaborate multivalent and/or multispecific molecules. This chapter aims at giving an overview of the published work using single domain antibodies to create bispecific antibodies.作者: 克制 時間: 2025-3-30 06:18
Pathologie der Harnleitermündungvation of T-cell proliferation and cytotoxicity in vivo..This design allows easy engineering of multispecificity in a single molecule, e.g., bispecific antibodies bivalent for the target and monovalent for effector activation (e.g., for T-cell activation), or trispecific antibodies ..作者: vanquish 時間: 2025-3-30 09:39
https://doi.org/10.1007/978-3-642-66519-6nufacturing. Several DVD-Ig? molecules have been constructed and characterized recently. In this chapter, we summarize the design considerations as well as functional, biophysical/biochemical, and pharmacokinetic properties of DVD-Ig? molecules. As examples, we provide details from our previously pu作者: 新字 時間: 2025-3-30 13:09
Die Technik der kystoskopischen Untersuchungell conformational changes in amino acid side chains – allows the binding site to adapt with high shape complementary to the two structurally unrelated antigens. Further, the dual binding function of bH1 has been improved to high affinity and validated by the potent dual action . and ., showing the 作者: CAGE 時間: 2025-3-30 19:07 作者: 果仁 時間: 2025-3-30 22:42
Technik des Harnleiterkatheterismusicacy is coupling of toxic payloads, such as chemotherapeutics or bacterial toxins (Alley et al. 2010). While the US market approval for the anti-CD33/calicheamycin conjugate Mylotarg., the first marketed drug of this kind, has been retracted in 2010, a novel generation of antibody drug conjugates (作者: 完成才能戰(zhàn)勝 時間: 2025-3-31 03:06
Technik des Harnleiterkatheterismusd antigen-presenting cells, respectively, in order to avoid side effects and vector sequestration. To this end, bispecific antibodies have been engineered as adapters that link the vector to a specific molecule on the targeted cell and at the same time block the interaction with the native virus rec作者: 蒙太奇 時間: 2025-3-31 05:13
pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed..978-3-642-43207-1978-3-642-20910-9作者: commensurate 時間: 2025-3-31 10:58
Bispecific Antibodies: Developments and Current Perspectives, can be further improved by protein and/or glyco-engineering (Carter 2006; Kubota et al. 2009). However, natural antibodies also face certain limitations. For example, antibodies are not capable of recruiting T cells because these cells do not express Fc receptors. Also, monoclonal antibodies are mo作者: 興奮過度 時間: 2025-3-31 13:55 作者: aqueduct 時間: 2025-3-31 20:02
Bispecific Single Domain Antibodies,em as ideal building blocks to elaborate multivalent and/or multispecific molecules. This chapter aims at giving an overview of the published work using single domain antibodies to create bispecific antibodies.作者: 縮影 時間: 2025-4-1 01:39
,Tribodies: Fab–scFv Fusion Proteins as a Platform to Create Multifunctional Pharmaceuticals,vation of T-cell proliferation and cytotoxicity in vivo..This design allows easy engineering of multispecificity in a single molecule, e.g., bispecific antibodies bivalent for the target and monovalent for effector activation (e.g., for T-cell activation), or trispecific antibodies ..作者: Nmda-Receptor 時間: 2025-4-1 01:55 作者: 入伍儀式 時間: 2025-4-1 08:29
Two-in-One Antibodies,ell conformational changes in amino acid side chains – allows the binding site to adapt with high shape complementary to the two structurally unrelated antigens. Further, the dual binding function of bH1 has been improved to high affinity and validated by the potent dual action . and ., showing the
